Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease

Background/Aims Inflammatory bowel disease (IBD) is characterised by chronic inflammation of the gastrointestinal tract, and encompasses both ulcerative colitis (UC) and Crohn’s disease (CD). Refractory disease is common, a combination of advanced drug therapies may be required to obtain maximal eff...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Robert Gilmore, Amrutha Murali, Amirah Etchegaray, Ei Swe, Yoon-Kyo An, Jakob Begun
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Korean Association for the Study of Intestinal Diseases 2025-10-01
Ráidu:	Intestinal Research
Fáttát:	upadacitinib vedolizumab combination therapy ulcerative colitis crohn disease
Liŋkkat:	http://irjournal.org/upload/pdf/ir-2024-00174.pdf
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!